A look at a clinical-stage biotech story about a gene-targeted obesity therapy; readers will learn what the article explores and why it matters.
Key Takeaways
- Study marks the next stage for a program that has already shown encouraging early signals
- Unlike the GLP-1 medicines that have reshaped obesity care over the past few years
- While today’s weight loss drugs have delivered unprecedented reductions in body weight